6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01353222 [Disease Site] Bladder Cancer [Description] 
A Randomized, Phase II, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description